Gilead Provides Update on U.S. Indication for Trodelvy® in …
1 day ago · Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response data from the global Phase 2, single-arm TROPHY-U-01 study. Continued approval for this indication was contingent on verification and description of clinical benefit in the confirmatory TROPiCS-04 study.
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated ...
21 hours ago · Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response data from the global Phase 2, single-arm TROPHY-U-01 study.
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
1 day ago · By Frank Vinluan on October 18, 2024. Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that ...
Gilead withdraws Trodelvy in bladder cancer after trial flop
1 day ago · Bladder cancer is a relatively small indication for Trodelvy, representing less than 10% of the drug’s sales, Gilead’s chief financial officer Andrew Dickinson said on the company’s second ...
Gilead withdraws Trodelvy in bladder cancer - Yahoo Finance
1 day ago · The FDA granted Trodelvy accelerated approval for bladder cancer in 2021, based on results that found it shrank tumors in people whose disease had progressed following treatment with chemotherapy ...
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy
1 day ago · Gilead Sciences is pulling its blockbuster breast-cancer drug Trodelvy from use in certain patients with bladder cancer following the failure of a confirmatory study. Gilead on Friday said it ...
Gilead to pull Trodelvy U.S. indication on trial setback - MSN
10m. Gilead (NASDAQ: GILD) on Friday announced plans to voluntarily withdraw a U.S. indication for its antibody-drug conjugate Trodelvy in bladder cancer after a late-stage confirmatory trial for ...
U.S. FDA Grants Accelerated Approval to Trodelvy for the …
Apr 13, 2021 · Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial …
1 day ago · The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead is withdrawing Trodelvy from the market in bladder cancer after a confirmatory study did not meet its primary endpoint.
Gilead withdraws bladder cancer drug in US after failed trial
1 day ago · GILD. (Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a ...
- Some results have been removed